|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||82.87 - 84.27|
|52 Week Range||68.00 - 94.21|
|Beta (5Y Monthly)||0.33|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||0.89 (1.04%)|
|Ex-Dividend Date||Mar 24, 2021|
|1y Target Est||N/A|
Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, obtained U.S. Food and Drug Administration (FDA) approval and clearance in the last month for its Cochlear™ Remote Assist solution in the Nucleus® and Baha® Systems. The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution are the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.
During May's Better Hearing and Speech Month, Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, is pleased to celebrate Lou Ferrigno, 69, actor, fitness expert and retired bodybuilder, receiving a cochlear implant and addressing his hearing loss. Taking the step to treat his profound sensorineural hearing loss with a cochlear implant will aid Ferrigno's desire to remain fit and healthy as he ages.
Adults with cochlear implants may be able to improve their listening and communications skills in daily life with the help of a new self-guided digital tool by Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions.